title: Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
abstract: BACKGROUND
  Lansoprazole is a H+.K(+)-ATPase (proton pump) inhibitor with an anti-secretory action and is therefore potentially useful in the treatment of gastro-oesophageal reflux.
  
  
  METHODS
  This study was conducted to determine the efficacy and short-term safety of lansoprazole at doses of 30 mg or 60 mg once daily, compared with ranitidine 150 mg twice daily, in the treatment of patients with reflux oesophagitis. This was a double-blind, stratified, randomized, comparative, parallel group study conducted in five centres in the UK. A total of 229 patients (155 men) aged 18-79 years with endoscopically-confirmed oesophagitis were randomized to receive lansoprazole 30 mg p.o. daily, lansoprazole 60 mg p.o. daily, or ranitidine 150 mg p.o. b.d. Efficacy was assessed by endoscopic examination at 4 weeks and 8 weeks, together with symptom relief and antacid usage.
  
  
  RESULTS
  Lansoprazole 30 mg and 60 mg were superior at 4 and 8 weeks (P < 0.01) to ranitidine in healing reflux oesophagitis: respective healing rates being 84%, 72% and 39% after 4 weeks and 92%, 91% and 53% after 8 weeks. Relief of heartburn with lansoprazole 30 mg and 60 mg was superior to that achieved with ranitidine at both week 4 (P < 0.01) and week 8 (P < 0.02). Sixty-four patients experienced a total of 85 adverse events, one-third of which were considered drug-related. The incidence and severity were similar in the three groups.
  
  
  CONCLUSIONS
  Lansoprazole 30 mg and 60 mg once daily are more effective than ranitidine 150 mg twice daily in the short-term treatment of reflux oesophagitis.
authors.affiliation: Rotherham District General Hospital, UK.
authors.forename: K D
authors.initials: KD
authors.lastname: Bardhan
authors.forename: C J
authors.initials: CJ
authors.lastname: Hawkey
authors.forename: R G
authors.initials: RG
authors.lastname: Long
authors.forename: A G
authors.initials: AG
authors.lastname: Morgan
authors.forename: K G
authors.initials: KG
authors.lastname: Wormsley
authors.forename: I K
authors.initials: IK
authors.lastname: Moules
authors.forename: D
authors.initials: D
authors.lastname: Brocklebank
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D005500:Follow-Up Studies; D017506:H(+)-K(+)-Exchanging ATPase / Q000494:pharmacology; D006261:Headache / Q000139:chemically induced; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D011899:Ranitidine; D017506:H(+)-K(+)-Exchanging ATPase; D009853:Omeprazole